SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Clinical trials addressing the potential effectiveness of drugs such as SGLT2 (sodium–glucose transport protein 2) inhibitors, GLP-1 (glucagon-like peptide 1) receptor agonists, obeticholic acid, pioglitazone, or saroglitazar in lean individuals with NAFLD are urgently needed [139].